Recent Quotes (30 days)

You have no recent quotes
chg | %

Cynapsus Therapeutics Inc  

(Public, CVE:CTH)   Watch this stock  
Find more results for CTH
0.620
+0.040 (6.90%)
Apr 24 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.60 - 0.63
52 week 0.27 - 1.51
Open 0.63
Vol / Avg. 837,965.00/367,412.00
Mkt cap 48.73M
P/E     -
Div/yield     -
EPS -0.12
Shares 78.60M
Beta 0.85
Inst. own     -

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -199.30% -205.34%
Return on average equity -499.82% -
Employees 6 -
CDP Score - -

Address

828 Richmond Street West
TORONTO, ON M6J 1C9
Canada
+1-416-7032449 (Phone)
+1-416-7038752 (Fax)

Website links

Description

Cynapsus Therapeutics Inc. is a specialty pharmaceutical company developing non-injectable delivery of apomorphine to be used as a rescue therapy for off motor symptoms of Parkinson�s disease. The Company�s drug candidate, APL-130277, is a fast-acting reformulation of apomorphine, which is approved in an injection formulation to rescue patients from off episodes. APL-130277 is a bilayer film that incorporates a neutralizing agent. The Company is focused on clinical development and maximizing the commercialization potential of APL-130277, primarily through a semi-virtual outsourcing business model integrating a team of formulation developers, active pharmaceutical ingredient (API) suppliers, regulatory and intellectual property experts, neuroscientists and central nervous system researchers.

Officers and directors

Rochelle E. Stenzler Independent Chairman of the Board
Age: 51
Anthony Giovinazzo President, Chief Executive Officer, Director
Andrew Williams Chief Financial Officer, Chief Operating Officer
Tomer Gold Director
Nan Hutchinson Director
Ilan Oren Director
Ronald G. Hosking Independent Director
Age: 69
Julia G. Levy Ph.D. Independent Director